# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Pierre Le Moyne d'Iberville (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET014-SYN
- Date: 2026-03-03
- Fictional facility: St. Posthumous Health Center
- Fictional author: Marguerite Delacroix-Boateng, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Two-week follow-up of recurrent fevers, seen the same day in infectious diseases. **S**

## History of present illness

Mr. Le Moyne d'Iberville returns two weeks after his first visit, on the day of his infectious diseases consultation with Dr. Okonkwo-Hale. He has had no fever, chills or sweats since then. The intake blood smears and rapid antigen test were negative, and the PCR sent to the reference laboratory at intake has detected Plasmodium vivax DNA. His quantitative G6PD activity is normal. He is not on any medicine and has no allergies. He is keen to be treated before the squadron's preparations take up all his time. **S**

| Element | Detail |
|---|---|
| Fever | None since intake |
| Results | Smears and rapid antigen test negative; PCR detected P. vivax DNA; G6PD normal |
| Medicines | None |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever, chills or sweats; tired at the end of the day |
| Gastrointestinal | Negative | No abdominal pain or jaundice |
| Genitourinary | Negative | No dark urine |

3 systems reviewed. **S**

## Current medications

- Chloroquine phosphate 500 mg tablet: 1,000 mg (two tablets) at once, then 500 mg at 6, 24 and 48 hours; take with food **S**
- Primaquine phosphate 26.3 mg tablet (15 mg base): two tablets (30 mg base) by mouth daily with food for 14 days **S**

## Allergies

- No known allergy **S**

## Objective

BP 122/76 mmHg; pulse 68 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 68.6 kg; BMI 22.4 kg/m². All vital signs are synthetic.

No condition-specific results recorded.

## Physical examination

| System | Finding |
|---|---|
| General | Well; temperature 36.6 C, blood pressure 122/76, pulse 68, weight 68.6 kg |
| Eyes | Sclerae white; mild conjunctival pallor |
| Abdomen | Spleen tip not palpable; liver not enlarged |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Relapsing Plasmodium vivax malaria** (B51.9). The presenting fevers now have their explanation. Three attacks of fever with chills, each months after leaving an area where P. vivax predominates, after blood-stage treatment alone, and P. vivax DNA in blood between attacks, fit relapses from dormant liver stages. Hemoglobin 13.0 g/dL and platelets 141 x10^3/uL are slightly low, consistent with recent attacks. G6PD activity 11.8 U/g Hb is normal, so primaquine is safe. Dr. Okonkwo-Hale recommends chloroquine for the blood stage, because P. vivax from the Central American coast is chloroquine-sensitive, with primaquine for radical cure. **S**
   - Chloroquine 1,000 mg now, then 500 mg at 6, 24 and 48 hours.
   - Primaquine 30 mg base daily with food for 14 days, starting today.
   - Report dark urine, breathlessness or blue lips at once.
   - Blood smear and PCR a week after finishing primaquine, and a blood count.
   - Review in four weeks.
2. **Pre-travel care for the deployment** (Z71.84). Dr. Okonkwo-Hale has drawn up the pre-travel plan: yellow fever vaccine (required for French Guiana), hepatitis A, hepatitis B if not immune, typhoid, malaria chemoprophylaxis, protection against mosquitoes and other vectors, food and water precautions, and terminal prophylaxis on return. **S**
   - Hepatitis B status from the preventive visit screening.
   - Vaccines at a pre-travel visit in the summer, well before departure.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Malaria diagnosis: smears, rapid antigen test and species PCR | At diagnosis | Completed today | Smears and rapid antigen test negative at intake; PCR from the intake sample detected P. vivax DNA |
| Laboratory | Quantitative G6PD activity before primaquine or tafenoquine | Once, before an 8-aminoquinoline | Completed today | 11.8 U/g Hb at intake, normal |
| Laboratory | Blood count and bilirubin for hemolysis on primaquine | Baseline, then after the course | Up to date | Hemoglobin 13.0 g/dL, platelets 141 x10^3/uL and bilirubin 1.1 mg/dL at intake; repeat after primaquine |
| Referral | Infectious diseases (travel medicine) consultation | Once | Completed today | Seen by Dr. Okonkwo-Hale today |
| Medication safety | Adverse effects: nausea, abdominal pain, dark urine, breathlessness, cyanosis | During the course | Completed today | Counseled before the first doses; take with food |
| Self-management | Relapse surveillance and the fever action plan | Every visit | Completed today | Fever card given: a smear the same day for any fever |
| Laboratory | Follow-up blood smear after treatment (ideally within one week of finishing) | About one week after finishing | Ordered | Smear and PCR ordered for a week after the last primaquine dose |

## Goal progress

- No further malaria relapse in the six months after radical cure. In progress; target 2026-10-13. **S**
- All required and recommended travel vaccines given, with a valid yellow fever certificate, at least ten days before departure. In progress; target 2026-10-13. **S**
- Knows to have a malaria test the same day for any fever, during travel and for months after return. In progress; target 2026-03-31. **S**

## Medication changes

- Started: Chloroquine phosphate 500 mg tablet: 1,000 mg (two tablets) at once, then 500 mg at 6, 24 and 48 hours; take with food **S**
- Started: Primaquine phosphate 26.3 mg tablet (15 mg base): two tablets (30 mg base) by mouth daily with food for 14 days **S**

## Guideline basis

- Treatment of Uncomplicated Malaria (clinical guidance) (2026), Centers for Disease Control and Prevention
- CDC Yellow Book: Health Information for International Travel, 2026 edition. Malaria (2026), Centers for Disease Control and Prevention
- The practice of travel medicine: guidelines by the Infectious Diseases Society of America (Hill DR, et al. Clin Infect Dis 2006;43(12):1499-1539) (2006), Infectious Diseases Society of America

## Follow-up

- Review in four weeks. **S**
- Next scheduled visit 2026-03-31: six-week review after chloroquine and primaquine: blood count, adverse effects, relapse surveillance. **S**
